Full-Time

Production Coach

Posted on 11/15/2025

Bachem

Bachem

1,001-5,000 employees

Develops and manufactures peptides and oligonucleotides

Compensation Overview

$83.6k - $115.1k/yr

+ Annual performance bonus + Comprehensive Medical/Dental/Vision coverage + Paid vacation + Personal and sick days

Carson, CA, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • Bachelor's Degree Organic Chemistry, Biochemistry, or the equivalent
  • Master's Degree Organic Chemistry, Biochemistry, or the equivalent (preferred)
  • 1-3 years experience in cGMP manufacturing and the related documentation standards, including safety, health and compliance regulations as specified by federal, state and local governments
  • 4-6 years pharmaceutical manufacturing (preferred)
  • Thorough understanding of all manufacturing stages and in-process analytical methods
  • Knowledge of the chemical composition, structure, and properties of substances and of the chemical processes and transformations that they undergo. This includes uses of chemicals and their interactions, danger signs, production techniques, and disposal methods. Knowledge of solvent, waste and materials flow is required
  • Familiar with and fully capable of operating and training on scientific manufacturing equipment and utilities
  • Experience working safely with hazardous materials and hazardous waste
  • Advanced computer knowledge, including Microsoft Office applications. SAP experience. (preferred)
  • Ability to work late shifts on a continuous basis and be flexible of working hours based on business needs which may include some nights and weekends
Responsibilities
  • Execute and support all production stages which include but are not limited to; synthesis, cleavage, cyclization, conjugation, purification, reconstitution, lyophilization and in-process analytics.
  • Sign off on steps requiring supervision, diagnose and troubleshoot equipment issues, make data-based decisions and escalate to appropriate parties when necessary.
  • Provide technical training and guidance on equipment, SOPs, and chemistry processes to support the ongoing development of each member of the team.
  • Ensures that all team member Master Control requirements are met in a timely manner.
  • Maintains training and certification records for team members, as needed.
  • Install, operate and maintain equipment for production and in-process testing.
  • The equipment includes but is not limited to analytical HPLC/UPLC, prep. HPLC systems, lyophilizers, balances, reactors, HF cleavage equipment, diafiltration systems, water purification systems, ovens, washing systems and others used in manufacturing.
  • Schedule work assignments and ensure team members are able to take timely rest breaks and meal periods and that all applicable hours are accurately captured on work orders.
  • Stand in for team members to cover breaks or lunches to ensure that a process continues, as needed.
  • Actively present in the labs to ensure that operations are running smoothly, and safety and compliance requirements are met.
  • Ensure operators are trained properly on the required standards of operations; BPR, SOPs, STMs, utilization, Safety standards, 5S standards, compliance, etc.
  • Approaches daily activities with a continuous improvement mindset.
  • Regularly identifies improvement initiatives and involves team members in ongoing improvement activities.
  • Ensure availability and safe, efficient use of the instruments, raw materials and other resources while scheduling production activities and communicating with all responsible departments involved.
  • Review BPRs, logbooks, other quality documents, as needed, but at least once daily.
  • Act as a witness to procedures as required.
  • Provide constructive feedback to Managers regarding team members performance.
  • Initiate, investigate and close quality events (Deviation, CAPA, etc.) in a timely manner.
  • Support investigations and implementation of corrective actions with technical knowledge.
  • Ensure seamless transfer of information and responsibilities across shifts and between areas.
  • Plan, attend and lead production huddles meetings representing production team, bringing knowledge of processes, equipment and schedule, as needed.
  • Ability to work late shifts on a continuous basis and be flexible of working hours based on business needs which may include some nights and weekends
Desired Qualifications
  • Master's Degree Organic Chemistry, Biochemistry, or the equivalent (preferred)
  • 4-6 years pharmaceutical manufacturing (preferred)
  • SAP experience (preferred)

Bachem provides development and manufacturing of peptides and oligonucleotides for research, clinical development, and commercial products. Its offerings include custom synthesis and scale-up production, analytical testing, and related services across the drug development spectrum. Customers work with Bachem by specifying desired sequences and specifications, after which Bachem designs, synthesizes, and quality-controls the peptides or oligonucleotides and delivers them in appropriate scales and formats. The company differentiates itself through more than five decades of experience, a global footprint with sites in Europe, the US, and Asia, and an integrated set of services spanning discovery support to commercial manufacturing. Its goal is to help pharmaceutical and biotechnology companies advance peptide- and oligonucleotide-based therapies by providing reliable, scalable, and well-supported manufacturing and development capabilities.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Bubendorf, Switzerland

Founded

1971

Simplify Jobs

Simplify's Take

What believers are saying

  • Oligonucleotide market expansion via TIRmed Pharma collaboration for atopic dermatitis.
  • CHF 500 million credit facility enables capacity expansion toward CHF 1B revenue target.
  • New CEO Anne-Kathrin Stoller brings Americas operational expertise and commercial focus.

What critics are saying

  • CEO transition disrupts execution of strategic growth initiatives through 2026.
  • Elevated debt servicing costs from syndicated facility erode 30% EBITDA margin target.
  • Chinese competitors scale oligonucleotide production at 40% lower costs via subsidies.

What makes Bachem unique

  • Leading peptide and oligonucleotide CDMO with 50+ years manufacturing expertise.
  • Integrated GMP capabilities for clinical-stage oligonucleotide therapeutics development.
  • Global footprint across Switzerland, US, and Europe with established pharma relationships.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Company News

Nordic Life Science
Nov 18th, 2025
TIRmed Pharma collaborates with Bachem

TIRmed Pharma collaborates with Bachem. The collaboration includes process development and manufacturing of TIR-01, the active substance in TIRmed's treatment for atopic dermatitis (eczema), and marks an important step towards future clinical trials. As part of its preclinical program, TIRmed Pharma is collaborating with Bachem to establish high-quality production processes for TIR-01, an oligonucleotide-based compound, they describe in a press release. With its expertise in oligonucleotide production, Bachem provides critical expertise for GMP development, ensuring stability, consistency and regulatory compliance for upcoming clinical studies according to the company. "The collaboration with Bachem is an important milestone in the work of taking our drug candidate further towards the clinic," says Leo Holmgren, CEO of TIRmed Pharma. "It gives us access to world-leading manufacturing expertise and strengthens the foundation for being able to offer patients a longer-term treatment alternative," he adds. Learn more about the science behind TIRmed Pharma and its connections to this year's Nobel Prize in Medicine in our latest issue of the magazine - out now!

CHEManager
Oct 31st, 2025
Anne-Kathrin Stoller Becomes New CEO at Bachem

Anne-Kathrin Stoller becomes new CEO at Bachem. Bachem announced today that the Board of Directors has appointed Anne-Kathrin Stoller, the former Head of Bachem Americas and previously the company's CMO for many years, as the new CEO effective january 1, 2026. She succeeds Thomas Meier, who has decided to take on a new challenge outside the company after more than thirty years at Bachem and almost six years as CEO. "Thomas Meier has contributed significantly to Bachem's continued success. Together with his team, he has achieved a capital-efficient and profitable growth. At the same time, Bachem's position as an innovative and reliable partner to the pharmaceutical industry has been further strengthened. We would like to express our sincere thanks to Thomas for his many years of service, his leadership and extraordinary contribution to Bachem," says Kuno Sommer, Chairman of the Board of Directors of Bachem. He continues: "I am very pleased that we have been able to appoint Anne-Kathrin Stoller, an experienced and competent successor from within our own ranks, as the new CEO. Anne-Kathrin has an excellent combination of expertise, leadership skills, and customer focus and, together with her colleagues in the Executive Committee, will continue Bachem's successful course." Thomas Meier, CEO, Bachem, added: "Bachem is a great company and has developed into a leading global, innovation-driven developer and manufacturer of peptides and oligonucleotides in recent years. I have had the privilege of helping to shape and accompany this development in various roles over the past three decades, and I am very grateful for the many enriching experiences I have had at work and the formative encounters with people. Above all, I would like to thank Bachem's employees and customers, as well as my colleagues in the Executive Committee and on the Board of Directors, for their active support and excellent cooperation." Anne-Kathrin Stoller, current Head of Bachem Americas and future CEO, Bachem, commented: "I am delighted to have earned the trust of the Board of Directors and will do everything in my power, together with the members of the Executive Committee and all Bachem employees, to continue our company's impressive success story. Under the leadership of Thomas Meier, Bachem has set the course for the future. I would like to thank him for his collegial support over the past years and everyone at Bachem who works hard every day to ensure that we make an important contribution to human health." Anne-Kathrin Stoller has worked for Bachem since 2006. After holding various management positions, including Head of Business Development & Sales Europe, Chief Marketing Officer and member of the Group Executive Board, she took on the role of Chief Operating Officer Americas in 2022 and is responsible for the company's US business. Anne-Kathrin Stoller studied chemistry in Hanover and Cambridge (UK) and holds a doctorate in bioorganic chemistry from the University of Basel.

Stock Titan
Aug 20th, 2025
Bachem Expands Corporate Executive Committee to Include Chief Operations Officer Role

Bachem (OTC:BCHMY) has announced the appointment of Hans Van Hees as Chief Operations Officer (COO), effective September 1, 2025.

Stock Titan
Jul 24th, 2025
Bachem Shows Strong Growth in the First Half of 2025

Looking ahead, Bachem aims to achieve annual sales exceeding CHF 1 billion and an EBITDA margin over 30% by 2026, supported by significant investments including the new Building K facility and planned expansion in Sisslerfeld.

PharmiWeb.com
Nov 27th, 2024
Green Manufacturing In Pharma: Sustainable Oligonucleotide Production On An Industrial Scale

Oligonucleotides are at the forefront of modern medicine, and have emerged as powerful tools in treating diseases in recent years. Oligonucleotides – short DNA or RNA molecules that host a range of applications in genetic testing, research, and forensics – have seen a marked growth in significance as therapeutics. As their clinical application widens, methods of production must be robust to ensure demand is met. Demand for oligonucleotides in medicines is steadily increasing, with pressing need for an eco-friendly manufacturing process which satisfies green manufacturing standards without compromising yield or process efficiency. Thus, the responsibility lies with manufacturers to ensure end users receive their medications, while striving for sustainable production methods

INACTIVE